Souhaitez-vous accéder aux communiqués récents ?

Charlotte, North Carolina, March 25, 2024 (GLOBE NEWSWIRE) -- Burn Boot Camp, a leading boutique fitness franchise, has teamed up with the Muscular Dystrophy Association (MDA) for its eighth annual...

New York, March 21, 2024 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association’s funding of foundational research leads to new drug approval by the US Food and Drug Administration (FDA) of Duvyzat...

New York, March 13, 2024 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) today announced its continued partnership with Nyheim Hines -- an NFL running back who has agreed to a new...

New data from the RESPOND study show that neurofilament levels, an indicator of neurodegeneration, were reduced in nearly all study participants treated with SPINRAZAReductions in biomarker complement...

CORAL GABLES, Fla., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on...

New York, Feb. 15, 2024 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) today announced Brooke Eby will be the keynote speaker at the 2024 MDA Clinical & Scientific...

New York, Jan. 22, 2024 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) announced today the opening of registration for both campers and volunteers for its MDA Summer Camp program. MDA...

New York, Dec. 21, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) announced today that long-term partner Acosta Group has reached a historic $100 million milestone in fundraising...

Catalyst Pharmaceuticals Reports Strong Third Quarter 2023 Financial Results

CORAL GABLES, Fla., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...